OraSure (OSUR) 10-K12 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Mar. 09, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	1116463
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		56,415,992
Entity Public Float			$473,975,954

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash	$92,867	$93,191
Short-term investments	5,000
Accounts receivable, net of allowance for doubtful accounts of $533 and $299	16,138	12,957
Inventories	15,763	11,444
Prepaid expenses	1,140	1,712
Deferred income taxes		71
Other current assets	306	200
Total current assets	131,214	119,575
PROPERTY AND EQUIPMENT, net	17,934	17,933
INTANGIBLE ASSETS, net	17,505	22,226
GOODWILL	21,734	23,782
OTHER ASSETS	1,246	729
TOTAL ASSETS	189,633	184,245
CURRENT LIABILITIES:
Accounts payable	7,148	4,834
Deferred revenue	8,043	1,119
Deferred income taxes	139
Accrued expenses	11,132	13,032
Total current liabilities	26,462	18,985
OTHER LIABILITIES	1,234	677
DEFERRED INCOME TAXES	3,236	3,437
COMMITMENTS AND CONTINGENCIES (Note 11)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 56,187 and 55,632 shares issued and outstanding	0	0
Additional paid-in capital	344,894	338,674
Accumulated other comprehensive loss	-7,848	-3,797
Accumulated deficit	-178,345	-173,731
Total stockholders' equity	158,701	161,146
Total liabilities and stockholders' equity	$189,633	$184,245

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$533	$299
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	120,000	120,000
Common stock, shares issued	56,187	55,632
Common stock, shares outstanding	56,187	55,632

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
NET REVENUES:
Product	$98,894	$98,317	$85,753
Licensing and product development	7,570	623	2,067
Total revenue	106,464	98,940	87,820
COST OF PRODUCTS SOLD	39,840	40,351	32,249
Gross profit	66,624	58,589	55,571
OPERATING EXPENSES:
Research and development	12,058	10,932	12,445
Sales and marketing	41,118	46,465	37,087
General and administrative	23,750	21,654	22,309
Gain on contract termination settlement	-5,500	-8,300
Total operating expenses	71,426	70,751	71,841
Operating loss	-4,802	-12,162	-16,270
INTEREST EXPENSE			-172
OTHER INCOME (EXPENSE)	531	200	-70
Loss before income taxes	-4,271	-11,962	-16,512
INCOME TAX EXPENSE (BENEFIT)	343	-772	-1,397
NET LOSS	($4,614)	($11,190)	($15,115)
LOSS PER SHARE:
BASIC	($0.08)	($0.20)	($0.29)
DILUTED	($0.08)	($0.20)	($0.29)
SHARES USED IN COMPUTING LOSS PER SHARE:
BASIC	55,949	55,555	51,457
DILUTED	55,949	55,555	51,457

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net loss	($4,614)	($11,190)	($15,115)
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments	-4,051	-3,131	1,298
Other comprehensive income (loss)	-4,051	-3,131	1,298
COMPREHENSIVE LOSS	($8,665)	($14,321)	($13,817)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
In Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2011	$100,250		$249,640	($1,964)	($147,426)
Beginning Balance, Shares at Dec. 31, 2011		47,393
Common stock issued upon exercise of options	10,040		10,040
Common stock issued upon exercise of options, Shares	1,476	1,476
Vesting of restricted stock	0	0	0	0	0
Vesting of restricted stock, Shares		454
Issuance of common stock for public equity offering	70,246		70,246
Issuance of common stock for public equity offering, Shares		6,100
Purchase and retirement of treasury shares	-1,560		-1,560
Purchase and retirement of treasury shares, Shares		-142
Compensation cost for restricted stock	2,894		2,894
Compensation cost for stock option grants	2,262		2,262
Net loss	-15,115				-15,115
Currency translation adjustments	1,298			1,298
Ending Balance at Dec. 31, 2012	170,315		333,522	-666	-162,541
Ending Balance, Shares at Dec. 31, 2012		55,281
Common stock issued upon exercise of options	409		409
Common stock issued upon exercise of options, Shares	80	80
Vesting of restricted stock	0	0	0	0	0
Vesting of restricted stock, Shares		395
Purchase and retirement of treasury shares	-829		-829
Purchase and retirement of treasury shares, Shares		-124
Compensation cost for restricted stock	2,878		2,878
Compensation cost for stock option grants	2,694		2,694
Net loss	-11,190				-11,190
Currency translation adjustments	-3,131			-3,131
Ending Balance at Dec. 31, 2013	161,146		338,674	-3,797	-173,731
Ending Balance, Shares at Dec. 31, 2013		55,632
Common stock issued upon exercise of options	1,115		1,115
Common stock issued upon exercise of options, Shares	249	249
Vesting of restricted stock	0	0	0	0	0
Vesting of restricted stock, Shares		428
Purchase and retirement of treasury shares	-639		-639
Purchase and retirement of treasury shares, Shares		-122
Compensation cost for restricted stock	2,663		2,663
Compensation cost for stock option grants	3,081		3,081
Net loss	-4,614				-4,614
Currency translation adjustments	-4,051			-4,051
Ending Balance at Dec. 31, 2014	$158,701		$344,894	($7,848)	($178,345)
Ending Balance, Shares at Dec. 31, 2014		56,187

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
OPERATING ACTIVITIES:
Net loss	($4,614)	($11,190)	($15,115)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation	5,744	5,572	5,197
Depreciation and amortization	6,307	6,552	7,250
Unrealized foreign currency (gain) loss	-305	49	-55
Deferred income taxes	294	-772	-1,397
Inventory purchase accounting step-up adjustment			16
Changes in assets and liabilities
Accounts receivable	-3,381	4,337	-220
Inventories	-4,401	1,268	-3,139
Prepaid expenses and other assets	475	51	-99
Accounts payable	2,194	1,510	-791
Deferred revenue	6,943	-4,365	4,178
Accrued expenses and other liabilities	-1,730	5,373	-1,198
Net cash provided by (used in) operating activities	7,526	8,385	-5,373
INVESTING ACTIVITIES:
Purchases of short-term investments	-9,407
Proceeds from maturities of short-term investments	4,432
Purchases of property and equipment	-3,005	-2,462	-2,019
Net cash used in investing activities	-7,980	-2,462	-2,019
FINANCING ACTIVITIES:
Repayments of long-term debt			-7,292
Proceeds from the issuance of common stock, net of expenses			70,246
Proceeds from exercise of stock options	1,115	409	10,040
Repurchase of common stock	-639	-829	-1,560
Net cash provided by (used in) financing activities	476	-420	71,434
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	-346	-200	-32
NET INCREASE (DECREASE) IN CASH	-324	5,303	64,010
CASH, BEGINNING OF PERIOD	93,191	87,888	23,878
CASH, END OF PERIOD	$92,867	$93,191	$87,888

The_Company

The Company	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
The Company	1	THE COMPANY:
	We develop, manufacture, market and sell diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care, tests that are processed in a laboratory, and a rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell oral fluid collection devices used to collect, stabilize and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our OTC HIV and cryosurgical products are available at retail pharmacies and mass merchandisers, and our OTC HIV product is also sold to consumers over the internet.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
	Principles of Consolidation and Basis of Presentation
	The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
	Supplemental Cash Flow Information
	On July 30, 2012, we repaid the balance of our long-term debt so we paid no interest during 2013 and 2014. In 2012, we paid interest of $199.

	In 2014 and 2013, we paid state income taxes of $31 and $27, respectively. In 2012, we paid foreign and state income taxes of $22.
	In 2014, 2013 and 2012, we recorded through the consolidated statements of operations an increase in our allowance for doubtful accounts of $253, $18 and $115, respectively.
	As of December 31, 2014, we had accruals for purchases of property and equipment of $217. We had no accruals for purchases of property and equipment as of December 31, 2013 or 2012.
	Short-Term Investments
	We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.
	Our available-for-sale securities as of December 31, 2014 consisted of guaranteed investment certificates with amortized cost and fair value of $5,000. As of December 31, 2013, we had no available-for-sale securities.
	Accounts Receivable
	Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.
	Inventories
	Inventories are stated at the lower of cost or market determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based primarily on the estimated forecast of product sales. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates. In addition to reserving for these items identified through specific identification procedures, we also reserve for unidentified scrap or spoilage under a fixed-formula methodology.
	Property and Equipment
	Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations.
	Intangible Assets
	Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. The customer list, acquired technology and tradenames were all part of our acquisition of DNAG in August 2011. Intangible assets are amortized using the straight-line method over their estimated useful lives of one to fifteen years.

	Goodwill
	Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with the respective carrying values.
	We performed our annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of December 31, 2014, we believe no indicators of impairment exist.
	Impairment of Long-Lived Assets
	We assess the recoverability of the affected long-lived assets, which include property and equipment and intangible assets, by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets.
	Revenue Recognition
	We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV test, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.
	We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at the gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the retail customer either in a store or over the internet. With the passage of time, however, we concluded that we had sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors.
	Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based upon currently available information, and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. It is recorded as licensing and product development revenue in our statements of operations.
	We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.
	On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick® HCV test in the United States. The product is used to test individuals at-risk for the hepatitis C virus (“HCV”). We are responsible for manufacturing and selling the product into all markets covered by this agreement.
	Pursuant to the Co-Promotion Agreement, we have granted exclusive co-promotion rights for the OraQuick® HCV test in certain markets to AbbVie and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick® HCV test. We have also jointly agreed with AbbVie to co-promote our OraQuick® HCV test in certain market segments, namely: healthcare providers such as primary care physicians, gastroenterologists, hepatologists and infectious disease specialists; employers and employee groups experiencing a high HCV prevalence rate, such as the long-haul trucking industry; and national retail pharmacies and retail clinics that perform routine healthcare screening services.
	In exchange for these exclusive rights and other services, we are eligible to receive up to $75,000 in aggregate payments over the term of the agreement, which runs through December 31, 2019. We plan to recognize the payments ratably on a monthly basis over the life of the agreement. In addition, if certain performance-based milestones are achieved, we will be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Payments received under this agreement will be recorded as licensing and product development revenue in our statements of operations.
	Customer Sales Returns and Allowances
	We do not grant product return rights to our customers for any product, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statement of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of December 31, 2014 and 2013, the reserve for sales returns and allowances was $437 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.
	Deferred Revenue
	We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2014 and 2013 includes customer prepayments of $613 and $1,119, respectively. Deferred revenue as of December 31, 2014 also includes $7,430 from AbbVie, which represents the $15,000 payment received in July 2014 under the terms of our HCV co-promotion agreement, less amounts recognized ratably in revenue.
	Customer and Vendor Concentrations
	We had no significant concentrations (greater than 10%) in accounts receivable as of December 31, 2014 and 2013. We had no significant concentrations (greater than 10%) in revenues for the years ended December 31, 2014, 2013, or 2012.
	We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
	Research and Development
	Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.
	Advertising Expenses
	Advertising costs are charged to expense as incurred. During 2014, 2013, and 2012, we incurred $6,910, $17,142, and $6,310, respectively, in advertising expenses.
	Stock-Based Compensation
	We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue restricted stock, we issue new shares rather than purchase shares on the open market.
	Income Taxes
	We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

	We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards.
	Foreign Currency Translation
	The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.
	Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.
	Loss Per Share
	Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 6,447, 5,924, and 5,314 shares were outstanding as of December 31, 2014, 2013 and 2012, respectively. As a result of our net losses for the years ended December 31, 2014, 2013 and 2012, these shares were excluded from the respective period’s computation of diluted loss per share, as their inclusion would have been anti-dilutive.
	Accumulated Other Comprehensive Loss
	We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.
	Our accumulated other comprehensive loss for 2014, 2013, and 2012 consisted of foreign currency translation adjustments.
	We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $(4,051), $(3,131) and $1,298 currency translation adjustments recorded in 2014, 2013 and 2012, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.
	Fair Value of Financial Instruments
As of December 31, 2014 and 2013, the carrying values of cash, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.
Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

	Level 1:	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

	Level 2:	Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

	Level 3:	Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of December 31, 2014 and 2013 was $1,234 and $677, respectively, and was calculated using the quoted market price of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. We are still evaluating the effects, if any, which adoption of this guidance will have on our consolidated financial statements

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	3	INVENTORIES:


			December 31,
			2014		2013
	Raw materials		$	8,539	$	6,700
	Work in process			898		833
	Finished goods			6,326		3,911

			$	15,763	$	11,444

Property_and_Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	4	PROPERTY AND EQUIPMENT:


			December 31,
			2014			2013
	Land		$	1,118		$	1,118
	Buildings and improvements			18,168			16,977
	Machinery and equipment			20,768			19,199
	Computer equipment and software			7,238			6,443
	Furniture and fixtures			1,765			1,731
	Construction in progress			293			855

				49,350			46,323
	Less accumulated depreciation			(31,416	)		(28,390	)

			$	17,934		$	17,933


	Depreciation expense was $3,123, $3,026, and $3,347 for 2014, 2013, and 2012, respectively.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
Goodwill and Other Intangible Assets	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	5	GOODWILL AND OTHER INTANGIBLE ASSETS:
	The changes in goodwill are as follows:


			December 31,
			2014				2013
	Balance as of January 1		$	23,782			$	25,445
	Decrease related to foreign currency translation			(2,048	)			(1,663	)

	Balance as of December 31		$	21,734			$	23,782

	Intangible assets consist of the following:


					December 31, 2014
			Amortization		Gross				Accumulated			Net
			Period (Years)		Gross				Amortization			Net
	Customer list		10		$	10,779			$	(3,508	)	$	7,271
	Patents and product rights		10-Mar			10,449				(7,957	)		2,492
	Acquired technology		7			8,372				(3,833	)		4,539
	Tradename		15			4,132				(929	)		3,203

					$	33,732			$	(16,227	)	$	17,505



					December 31, 2013
			Amortization		Gross				Accumulated			Net
			Period (Years)		Gross				Amortization			Net
	Customer list		10		$	11,795			$	(2,701	)	$	9,094
	Patents and product rights		10-Mar			10,449				(7,466	)		2,983
	Acquired technology		7			9,162				(2,952	)		6,210
	Tradename		15			4,521				(715	)		3,806
	Non-compete agreements		3-Jan			787				(654	)		133

					$	36,714			$	(14,488	)	$	22,226

	Patents and products rights are made up of the following:


			December 31,
			2014				2013
	HIV-related		$	1,900			$	1,900
	HCV-related			4,500				4,500
	Lateral flow-related			1,500				1,500
	Cryosurgery-related			2,549				2,549

				10,449				10,449
	Less accumulated amortization			(7,957	)			(7,466	)

			$	2,492			$	2,983

	Amortization expense for 2014, 2013, and 2012 was $3,184, $3,526, and $3,903, respectively.

	Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


	2015		$	3,016
	2016			3,016
	2017			3,016
	2018			3,012
	2019			1,826
	Beyond			3,619

Accrued_Expenses

Accrued Expenses	12 Months Ended
Accrued Expenses	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses	6	ACCRUED EXPENSES:


			December 31,
			2014		2013
	Payroll and related benefits		$	6,620	$	5,827
	Royalties			2,285		4,374
	Professional fees			480		749
	Other			1,747		2,082

			$	11,132	$	13,032

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	7	INCOME TAXES:
	Income (loss) before income tax expense (benefit) consists of the following:


			Years Ended December 31,
			2014				2013				2012
	United States		$	(8,282	)		$	(12,833	)		$	(13,515	)
	Canada			4,011				871				(2,997	)

			$	(4,271	)		$	(11,962	)		$	(16,512	)

	The components of the income tax expense (benefit) are as follows:


			Years Ended December 31,
			2014				2013				2012
	Current
	Federal		$	—			$	—			$	—
	State			—				—				—
	Canada			49				—				—

				49				—				—

	Deferred
	Federal			(2,248	)			(4,280	)			(4,370	)
	State			(827	)			(323	)			(272	)
	Canada			294				(772	)			(1,397	)

				(2,781	)			(5,375	)			(6,039	)
	Increase in valuation allowance			3,075				4,603				4,642

				294				(772	)			(1,397	)

	Total income tax expense (benefit)		$	343			$	(772	)		$	(1,397	)


	For the year ended December 31, 2014, we recorded foreign tax expense of $343. For the years ended December 31, 2013 and 2012, we recorded foreign tax benefits of $772 and $1,397, respectively, associated with certain Canadian research and development and investment tax credits and DNAG’s loss before income taxes in 2012. The income tax benefit associated with DNAG was considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG. The deferred tax benefit for the year ended December 31, 2012 was negatively impacted by a $428 adjustment to DNAG’s deferred tax liability recorded in the second quarter of 2012 to reflect a change in the enacted Canadian provincial tax rates.
	A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2014, 2013, and 2012 is as follows:


			2014				2013				2012
	Statutory U.S. federal income tax rate			(34.0	)%			(34.0	)%			(34.0	)%
	State income taxes, net of federal benefit			(6.4	)			(1.6	)			(1.2	)
	Canadian income taxes			8				(6.5	)			(8.5	)
	Nondeductible expenses and other			4				(0.4	)			1
	U.S. research and development credits			(0.7	)			—				(0.3	)
	Change in valuation allowance, federal and state			37.1				36				34.5

	Effective tax rate			8	%			(6.5	)%			(8.5	)%

	Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of our deferred tax assets (liabilities) as of December 31, 2014 and 2013 are as follows:


			2014				2013
	Deferred tax assets (liabilities):
	Net operating loss carryforwards		$	28,547			$	25,751
	Inventories			1,758				1,531
	Capitalized research and development costs			4,528				5,276
	Accruals and reserves currently not deductible			2,528				2,048
	Acquired intangible assets			(3,978	)			(5,099	)
	Depreciation and amortization			(485	)			114
	Stock-based compensation			5,369				4,704
	Investment tax credit carryforward			597				1,230
	Research and development tax credit carryforward			1,833				2,076

Net deferred tax asset			40,697				37,631
Valuation allowance			(44,072	)			(40,997	)

Net deferred tax liability		$	(3,375	)		$	(3,366	)

In assessing the realizability of our net deferred tax asset, we consider all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. In 2008, we established a full valuation allowance against our U.S. net deferred tax asset, and management believes the full valuation allowance is still appropriate as of December 31, 2014 and 2013 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the years ended December 31, 2014, 2013, or 2012.

Our Federal NOL carryforwards expire as follows:


Year of Expiration		NOLs
2018 - 2019		$	16,377
2020 - 2024			16,398
2025 - 2031			14,476
2032 - 2034			33,416

		$	80,667

The Tax Reform Act of 1986 contains provisions that limit the annual amount of NOLs available to be used in any given year in the event of a significant change in ownership. On September 29, 2000, two separate companies, STC Technologies, Inc. and Epitope, Inc., merged to form OraSure. A significant change in ownership, as defined by Section 382 of the Internal Revenue Code, occurred in connection with this merger. As such, the utilization of NOLs generated prior to September 29, 2000 is limited to approximately $13,700 per year. We do not believe that this limitation will have a material adverse impact on the utilization of our Federal NOL carryforwards in future years.
As of December 31, 2014, our gross unrecognized tax benefits totaled $2,073 and based upon the valuation allowance for our U.S. operations, the recognition of any tax benefit would not impact our effective tax rate. We record interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2014, 2013 and 2012. As a result of our net operating loss carryforward position, we are subject to audit by the Internal Revenue Service since our inception, as well as by several state jurisdictions for the years ended December 31, 2001 through 2014.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:


		2014				2013				2012
Balance as of January 1		$	2,051			$	2,011			$	2,015
Additions for tax positions of prior periods			25				40				67
Reductions for tax positions of prior periods			(3	)			—				(71	)

Balance as of December 31		$	2,073			$	2,051			$	2,011

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	8	STOCKHOLDERS’ EQUITY:
	Stock-Based Awards
	We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue restricted stock, we issue new shares rather than purchase shares on the open market.
	Under the terms of the Stock Plan, nonqualified options may be granted to eligible employees, including our officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

	As of December 31, 2014, 4,770 shares were available for future grants under the Stock Plan.
	The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


			Years Ended December 31,
			2014				2013				2012
	Black-Scholes Option Valuation Assumptions
	Risk-free interest rate(1)			2.13	%			1.47	%			0.99	%
	Expected dividend yield			—				—				—
	Expected stock price volatility(2)			50	%			51	%			52	%
	Expected life of stock options (in years)(2)			7				7				6

	(1)	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.
	(2)	Based upon historical experience.
	The weighted-average grant date fair value of stock options granted during the years ended December 31, 2014, 2013 and 2012 was $3.03, $3.58 and $5.38, respectively.
	Compensation expense recognized in the financial statements related to stock options was as follows:


			Years Ended December 31,
			2014				2013				2012
	Total compensation cost during the year		$	3,081			$	2,694			$	2,262
	Amounts capitalized into inventory during the year			(148	)			(128	)			(90	)
	Amounts recognized in cost of products sold for amounts previously capitalized			128				99				58

	Amounts charged against income		$	3,061			$	2,665			$	2,230

	The aggregate intrinsic value of options exercised during the years ended December 31, 2014, 2013, and 2012 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $901, $125, and $6,961, respectively.

	The following table summarizes the stock option activity under the Stock Plan:


			Options				Weighted-Average				Weighted-Average				Aggregate
							Exercise Price Per				Remaining				Intrinsic
							Share				Contractual Term				Value
	Outstanding on January 1, 2012			5,416			$	6.89
	Granted			783				11.18
	Exercised			(1,476	)			6.8
	Expired			(12	)			6.07
	Forfeited			(67	)			7.49

	Outstanding on December 31, 2012			4,644				7.64
	Granted			984				6.94
	Exercised			(80	)			5.07
	Expired			(82	)			7.59
	Forfeited			(195	)			7.87

	Outstanding on December 31, 2013			5,271				7.54
	Granted			1,202				5.77
	Exercised			(249	)			5.09
	Expired			(388	)			8.38
	Forfeited			(96	)			7.43

	Outstanding on December 31, 2014			5,740			$	7.22				6.3			$	18,084

	Vested or expected to vest as of December 31, 2014			5,679			$	7.23				6.3			$	17,826

	Exercisable on December 31, 2014			3,844			$	7.52				5.2			$	11,028

	As of December 31, 2014, there was $5,412 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 2.6 years.
Net cash proceeds from the exercise of stock options were $1,115, $409 and $10,040 for the years ended December 31, 2014, 2013, and 2012, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.
The following table summarizes information about stock options outstanding as of December 31, 2014:


Options outstanding														Options exercisable
Range of exercise prices		Number				Weighted-				Weighted-				Number			Weighted-
		Outstanding				Average				Average				Exercisable			Average
						Remaining				Exercise							Exercise
						Contractual				Price Per							Price Per
						Term				Share							Share
						(in years)
$2.55 - $5.19			726				7.8			$	4.49				726		$	4.49
$5.60			92				0.1				5.6				92			5.6
$5.71			1,136				9.1				5.71				—			—
$5.72 - $6.37			217				7.2				5.96				146			5.96
$6.63			670				5.9				6.63				643			6.63
$6.67 - $6.99			29				9				6.93				1			6.67
$7.05			758				8				7.05				355			7.05
$7.33 - $8.28			847				3.4				8.02				804			8.05
$8.33 - $10.89			597				1.5				9.35				593			9.34
$10.99 - $12.14			668				6.9				11.29				484			11.29

			5,740				6.3			$	7.22				3,844		$	7.52

The Stock Plan also permits us to grant restricted shares of our common stock to eligible employees, including officers, and our outside directors. Generally, these shares are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by the Compensation Committee of our Board of Directors. The market value of these shares at the date of grant is recognized on a straight-line basis over the period during which the restrictions lapse. Compensation cost of $2,663, $2,878 and $2,894 related to restricted shares was recognized during the years ended December 31, 2014, 2013, and 2012, respectively.
The following table summarizes restricted stock award activity under the Stock Plan:


		Shares				Weighted-Average
						Grant Date Fair
						Value
Issued and unvested, January 1, 2012			879			$	5.91
Granted			259				11.31
Vested			(454	)			5.56
Forfeited			(14	)			7.77

Issued and unvested, December 31, 2012			670				8.19
Granted			438				6.3
Vested			(395	)			7.81
Forfeited			(60	)			8.27

Issued and unvested, December 31, 2013			653				7.15
Granted			506				5.82
Vested			(428	)			6.65
Forfeited			(24	)			7.38

Issued and unvested, December 31, 2014			707			$	6.5

Issued and expected to vest, December 31, 2014			707			$	6.5

As of December 31, 2014, there was $2,505 of unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 1.7 years.
In connection with the vesting of restricted shares and exercise of stock options during the years ended December 31, 2014, 2013 and 2012, we purchased and immediately retired 122, 124 and 142 shares with aggregate values of $639, $829 and $1,560, respectively, in satisfaction of minimum tax withholding and exercise obligations.
Share Repurchase Program
On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired in 2014, 2013 or 2012.
Public Equity Offering
On July 11, 2012, we completed a public offering of 6,100 common shares, at a price of $12.30 per share, raising $75,030 before expenses of the offering. In connection with the offering, we paid $4,502 in underwriting discounts and commissions and incurred $282 in additional offering expenses.

Termination_Settlement

Termination Settlement	12 Months Ended
	Dec. 31, 2014
Extraordinary and Unusual Items [Abstract]
Termination Settlement	9	TERMINATION SETTLEMENT:
	On November 21, 2013, we terminated our assay collaboration agreement with Roche Diagnostics (“Roche”). Pursuant to this termination agreement, Roche paid us $8,300 which was recorded as a reduction of operating expense on our consolidated statement of operations for the quarter ended December 31, 2013. Roche agreed to provide certain transitional product support services to us and to supply certain of the assays developed under the collaboration on a transitional basis for up to five years following the termination. We had the right to stop the supply of assays prior to the end of this five-year period and to receive an additional payment from Roche of up to $5.5 million depending on how early in that five-year period the supply obligation was ended. During the second quarter of 2014, we issued our final purchase order for fully-automated assays previously developed under the terminated collaboration and as such, have recorded $5,500 as a reduction of operating expense in our consolidated statement of operations.

Business_Segment_Information

Business Segment Information	12 Months Ended
Business Segment Information	Dec. 31, 2014
Segment Reporting [Abstract]
Business Segment Information	10	BUSINESS SEGMENT INFORMATION:
	We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of diagnostic products, specimen collection devices and medical devices; and our molecular collection systems or “DNAG” business, which consists primarily of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products primarily result from sales to retail pharmacies and mass merchandisers and to consumers over the internet. OSUR also derives revenues from licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing. DNAG products are also sold into the academic research market, which consists of research laboratories, universities and hospitals.
	We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.
	The following table summarizes segment information for the years ended December 31, 2014, 2013, and 2012:


			Years Ended December 31,
			2014			2013			2012
	Net revenues:
	OSUR		$	82,686		$	78,559		$	73,562
	DNAG			23,778			20,381			14,258

	Total		$	106,464		$	98,940		$	87,820

	Operating income (loss):
	OSUR		$	(8,324	)	$	(12,849	)	$	(13,395	)
	DNAG			3,522			687			(2,875	)

	Total		$	(4,802	)	$	(12,162	)	$	(16,270	)

	Depreciation and amortization:
	OSUR		$	3,254		$	3,225		$	3,530
	DNAG			3,053			3,327			3,720

	Total		$	6,307		$	6,552		$	7,250

	Capital expenditures:
	OSUR		$	2,170		$	1,687		$	1,794
	DNAG			835			775			225

	Total		$	3,005		$	2,462		$	2,019


			December 31,
			2014			2013
	Total assets:
	OSUR		$	136,542		$	130,848
	DNAG			53,091			53,397

	Total		$	189,633		$	184,245


	Our products are sold principally in the United States and Europe.
	The following table represents total net revenues by geographic area, based on the location of the customer:


			Years Ended December 31,
			2014			2013			2012
	United States		$	82,256		$	77,194		$	67,460
	Europe			13,913			11,081			10,131
	Other regions			10,295			10,665			10,229

			$	106,464		$	98,940		$	87,820

	The following table represents total long-lived assets by geographic area:


			December 31,
			2014			2013
	United States		$	16,570		$	16,925
	Canada			1,353			975
	Other regions			11			33

			$	17,934		$	17,933

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11	COMMITMENTS AND CONTINGENCIES:
	Sublicense Agreement
	In June 2004, we entered into a sublicense agreement with a third party, pursuant to which we have been granted a limited, worldwide, non-exclusive sublicense to certain HIV-2 patents held by such party. Under the terms of this sublicense agreement, we are obligated to pay royalties based on a percentage of our net sales of certain products, which incorporate the technology covered by the licensed patents. Royalties are expensed as an element of cost of goods sold. Future minimum payments under this agreement are as follows:


	2015		$	500
	2016			500
	2017			500
	2018			292

			$	1,792

	Royalties from our commercial sale of products covered by the sublicense can be credited against these minimum royalty obligations.
	Leases
	We lease office space for our Canadian subsidiary and domestic warehouse facilities under operating lease agreements. Future payments required under these non-cancelable leases are as follows:


	2015		$	380
	2016			6

			$	386

	Rent expense for 2014, 2013 and 2012 was $648, $600, and $510, respectively.

	Purchase Commitments
	As of December 31, 2014, we had outstanding non-cancelable purchase commitments in the amount of $8,729 related to inventory, capital expenditures, and other goods or services.
	Employment Agreements
	Under terms of employment agreements with certain executive officers, which extend through 2016, we are required to pay each individual a base salary for continuing employment with us. The agreements require payments totaling $2,324 and $1,097 in 2015 and 2016, respectively.
	Litigation
	From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions are not expected to have, either individually or in the aggregate, a material adverse effect on our future financial position or results of operations.

Retirement_Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Retirement Plans	12	RETIREMENT PLANS:
	Substantially all of our U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for us to match employee contributions up to $4 per year. We contributed to the 401(k) Plan, net of forfeitures, $565, $553, and $592 in 2014, 2013, and 2012, respectively.
	In addition to our 401(k) plan, we offer a nonqualified deferred compensation plan to permit eligible highly compensated employees of the Company to defer receipt and taxation of their compensation each year. We also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2014 and 2013, the value of the assets associated with this plan was $1,234 and $677, respectively, and is included in other assets in our consolidated balance sheet. Our obligation related to the deferred compensation plan is included in other liabilities in our consolidated balance sheet. As of December 31, 2014 and 2013, our total obligation under this plan was $1,234 and $677, respectively.
	Effective January 2, 2012, all regular full-time employees of DNAG are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Revenue Canada. The RRSP also provides for DNAG to match employee contributions up to $2 per year. We contributed to the RRSP $136, $126, and $113 in 2014, 2013, and 2012, respectively.

Quarterly_Data

Quarterly Data	12 Months Ended
Quarterly Data	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Data	13	QUARTERLY DATA (Unaudited):
	The following tables summarize the quarterly results of operations for each of the quarters in 2014 and 2013. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein.


			2014 Results
			Three months ended
			March 31,			June 30,			September 30,			December 31,
			2014			2014			2014			2014
	Net revenues		$	23,537		$	26,401		$	27,845		$	28,681
	Costs and expenses			29,155			23,904	(1)		26,963			31,244

	Operating income (loss)			(5,618	)		2,497			882			(2,563	)
	Other income (expense), net			118			(142	)		268			287

	Income (loss) before income taxes			(5,500	)		2,355			1,150			(2,276	)
	Income tax expense (benefit)			131			(174	)		10			376

	Net income (loss)		$	(5,631	)	$	2,529		$	1,140		$	(2,652	)

	Earnings (loss) per share
	Basic		$	(0.10	)	$	0.05		$	0.02		$	(0.05	)

	Diluted		$	(0.10	)	$	0.04		$	0.02		$	(0.05	)


	(1)	Includes a $5.5 million gain from the termination of the Company’s oral fluid assay collaboration with Roche Diagnostics, which was recorded as a reduction of operating expenses in the indicated period.


			2013 Results
			Three months ended
			March 31,			June 30,			September 30,			December 31,
			2013			2013			2013			2013
	Net revenues		$	21,164		$	24,337		$	24,671		$	28,768	(2)
	Costs and expenses			31,753			29,913			26,731			22,705	(3)

	Operating income (loss)			(10,589	)		(5,576	)		(2,060	)		6,063
	Other income (expense), net			(47	)		42			41			164

	Income (loss) before income taxes			(10,636	)		(5,534	)		(2,019	)		6,227
	Income tax expense (benefit)			(410	)		(249	)		(127	)		14

	Net income (loss)		$	(10,226	)	$	(5,285	)	$	(1,892	)	$	6,213

	Earnings (loss) per share
	Basic		$	(0.18	)	$	(0.10	)	$	(0.03	)	$	0.11

	Diluted		$	(0.18	)	$	(0.10	)	$	(0.03	)	$	0.11


	(2)	Includes a non-recurring net favorable $2.5 million adjustment to account for a change in the Company’s revenue recognition policy related to its OraQuick® In-Home HIV tests.
	(3)	Includes an $8.3 million gain from the termination of the Company’s oral fluid assay collaboration with Roche Diagnostics, which was recorded as a reduction of operating expenses in the current period.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation
	The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.
Use of Estimates	Use of Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
Supplemental Cash Flow Information	Supplemental Cash Flow Information
	On July 30, 2012, we repaid the balance of our long-term debt so we paid no interest during 2013 and 2014. In 2012, we paid interest of $199.

	In 2014 and 2013, we paid state income taxes of $31 and $27, respectively. In 2012, we paid foreign and state income taxes of $22.
	In 2014, 2013 and 2012, we recorded through the consolidated statements of operations an increase in our allowance for doubtful accounts of $253, $18 and $115, respectively.
	As of December 31, 2014, we had accruals for purchases of property and equipment of $217. We had no accruals for purchases of property and equipment as of December 31, 2013 or 2012.
Short-Term Investments	Short-Term Investments
	We consider all short-term investments to be available-for-sale securities. These securities are comprised of guaranteed investment certificates with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.
	Our available-for-sale securities as of December 31, 2014 consisted of guaranteed investment certificates with amortized cost and fair value of $5,000. As of December 31, 2013, we had no available-for-sale securities.
Accounts Receivable	Accounts Receivable
	Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.
Inventories	Inventories
	Inventories are stated at the lower of cost or market determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based primarily on the estimated forecast of product sales. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates. In addition to reserving for these items identified through specific identification procedures, we also reserve for unidentified scrap or spoilage under a fixed-formula methodology.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations.
Intangible Assets	Intangible Assets
	Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. The customer list, acquired technology and tradenames were all part of our acquisition of DNAG in August 2011. Intangible assets are amortized using the straight-line method over their estimated useful lives of one to fifteen years.
Goodwill	Goodwill
	Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with the respective carrying values.
	We performed our annual impairment assessment as of July 31, 2014 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of December 31, 2014, we believe no indicators of impairment exist.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	We assess the recoverability of the affected long-lived assets, which include property and equipment and intangible assets, by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets.
Revenue Recognition	Revenue Recognition
	We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV test, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.
	We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at the gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the retail customer either in a store or over the internet. With the passage of time, however, we concluded that we had sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors.
	Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based upon currently available information, and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations.
	Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. It is recorded as licensing and product development revenue in our statements of operations.
	We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.
	On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie Inc. (“AbbVie”), to co-promote our OraQuick® HCV test in the United States. The product is used to test individuals at-risk for the hepatitis C virus (“HCV”). We are responsible for manufacturing and selling the product into all markets covered by this agreement.
	Pursuant to the Co-Promotion Agreement, we have granted exclusive co-promotion rights for the OraQuick® HCV test in certain markets to AbbVie and we have agreed to develop, implement, administer and maintain a patient care database for the exclusive use of AbbVie. This patient care database will be used to compile patient information regarding new individuals who have tested positive for HCV using our OraQuick® HCV test. We have also jointly agreed with AbbVie to co-promote our OraQuick® HCV test in certain market segments, namely: healthcare providers such as primary care physicians, gastroenterologists, hepatologists and infectious disease specialists; employers and employee groups experiencing a high HCV prevalence rate, such as the long-haul trucking industry; and national retail pharmacies and retail clinics that perform routine healthcare screening services.
	In exchange for these exclusive rights and other services, we are eligible to receive up to $75,000 in aggregate payments over the term of the agreement, which runs through December 31, 2019. We plan to recognize the payments ratably on a monthly basis over the life of the agreement. In addition, if certain performance-based milestones are achieved, we will be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31, 2015. The agreement also contains certain termination, indemnification and other provisions, typical of agreements of this type. Payments received under this agreement will be recorded as licensing and product development revenue in our statements of operations.
Customer Sales Returns and Allowances	Customer Sales Returns and Allowances
	We do not grant product return rights to our customers for any product, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statement of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of December 31, 2014 and 2013, the reserve for sales returns and allowances was $437 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.
Deferred Revenue	Deferred Revenue
	We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2014 and 2013 includes customer prepayments of $613 and $1,119, respectively. Deferred revenue as of December 31, 2014 also includes $7,430 from AbbVie, which represents the $15,000 payment received in July 2014 under the terms of our HCV co-promotion agreement, less amounts recognized ratably in revenue.
Customer and Vendor Concentrations	Customer and Vendor Concentrations
	We had no significant concentrations (greater than 10%) in accounts receivable as of December 31, 2014 and 2013. We had no significant concentrations (greater than 10%) in revenues for the years ended December 31, 2014, 2013, or 2012.
	We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
Research and Development	Research and Development
	Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.
Advertising Expenses	Advertising Expenses
	Advertising costs are charged to expense as incurred. During 2014, 2013, and 2012, we incurred $6,910, $17,142, and $6,310, respectively, in advertising expenses.
Stock-Based Compensation	Stock-Based Compensation
	We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue restricted stock, we issue new shares rather than purchase shares on the open market.
Income Taxes	Income Taxes
	We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

	We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards.
Foreign Currency Translation	Foreign Currency Translation
	The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.
	Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.
Loss Per Share	Loss Per Share
	Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 6,447, 5,924, and 5,314 shares were outstanding as of December 31, 2014, 2013 and 2012, respectively. As a result of our net losses for the years ended December 31, 2014, 2013 and 2012, these shares were excluded from the respective period’s computation of diluted loss per share, as their inclusion would have been anti-dilutive.
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss
	We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.
	Our accumulated other comprehensive loss for 2014, 2013, and 2012 consisted of foreign currency translation adjustments.
	We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $(4,051), $(3,131) and $1,298 currency translation adjustments recorded in 2014, 2013 and 2012, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	As of December 31, 2014 and 2013, the carrying values of cash, short-term investments, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.
	Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

		Level 1:	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

		Level 2:	Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

		Level 3:	Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of December 31, 2014 and 2013 was $1,234 and $677, respectively, and was calculated using the quoted market price of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in other assets with the same amount included in other liabilities in the accompanying consolidated balance sheets.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, ASU 2014-09 Revenue from Contracts with Customers. The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016, with no early adoption permitted. We are still evaluating the effects, if any, which adoption of this guidance will have on our consolidated financial statements

Inventories_Tables

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventories
		December 31,
		2014		2013
	Raw materials	$	8,539	$	6,700
	Work in process		898		833
	Finished goods		6,326		3,911

		$	15,763	$	11,444

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment
		December 31,
		2014			2013
	Land	$	1,118		$	1,118
	Buildings and improvements		18,168			16,977
	Machinery and equipment		20,768			19,199
	Computer equipment and software		7,238			6,443
	Furniture and fixtures		1,765			1,731
	Construction in progress		293			855

			49,350			46,323
	Less accumulated depreciation		(31,416	)		(28,390	)

		$	17,934		$	17,933

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
Goodwill and Other Intangible Assets (Tables)	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Goodwill	The changes in goodwill are as follows:


		December 31,
		2014				2013
	Balance as of January 1	$	23,782			$	25,445
	Decrease related to foreign currency translation		(2,048	)			(1,663	)

	Balance as of December 31	$	21,734			$	23,782

Summary of Intangible Assets	Intangible assets consist of the following:


				December 31, 2014
		Amortization		Gross				Accumulated			Net
		Period (Years)		Gross				Amortization			Net
	Customer list	10		$	10,779			$	(3,508	)	$	7,271
	Patents and product rights	10-Mar			10,449				(7,957	)		2,492
	Acquired technology	7			8,372				(3,833	)		4,539
	Tradename	15			4,132				(929	)		3,203

				$	33,732			$	(16,227	)	$	17,505



				December 31, 2013
		Amortization		Gross				Accumulated			Net
		Period (Years)		Gross				Amortization			Net
	Customer list	10		$	11,795			$	(2,701	)	$	9,094
	Patents and product rights	10-Mar			10,449				(7,466	)		2,983
	Acquired technology	7			9,162				(2,952	)		6,210
	Tradename	15			4,521				(715	)		3,806
	Non-compete agreements	3-Jan			787				(654	)		133

				$	36,714			$	(14,488	)	$	22,226

Summary of Patents and Products Rights	Patents and products rights are made up of the following:


		December 31,
		2014				2013
	HIV-related	$	1,900			$	1,900
	HCV-related		4,500				4,500
	Lateral flow-related		1,500				1,500
	Cryosurgery-related		2,549				2,549

			10,449				10,449
	Less accumulated amortization		(7,957	)			(7,466	)

		$	2,492			$	2,983

Summary of Amortization Expense	Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:


	2015	$	3,016
	2016		3,016
	2017		3,016
	2018		3,012
	2019		1,826
	Beyond		3,619

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
Accrued Expenses (Tables)	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Expenses
		December 31,
		2014		2013
	Payroll and related benefits	$	6,620	$	5,827
	Royalties		2,285		4,374
	Professional fees		480		749
	Other		1,747		2,082

		$	11,132	$	13,032

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) Before Income Tax Expense (Benefit)	Income (loss) before income tax expense (benefit) consists of the following:


		Years Ended December 31,
		2014			2013			2012
	United States	$	(8,282	)	$	(12,833	)	$	(13,515	)
	Canada		4,011			871			(2,997	)

		$	(4,271	)	$	(11,962	)	$	(16,512	)

Components of Income Tax Expense (Benefit)	The components of the income tax expense (benefit) are as follows:


		Years Ended December 31,
		2014			2013			2012
	Current
	Federal	$	—		$	—		$	—
	State		—			—			—
	Canada		49			—			—

			49			—			—

	Deferred
	Federal		(2,248	)		(4,280	)		(4,370	)
	State		(827	)		(323	)		(272	)
	Canada		294			(772	)		(1,397	)

			(2,781	)		(5,375	)		(6,039	)
	Increase in valuation allowance		3,075			4,603			4,642

			294			(772	)		(1,397	)

	Total income tax expense (benefit)	$	343		$	(772	)	$	(1,397	)

Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate	A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2014, 2013, and 2012 is as follows:


		2014			2013			2012
	Statutory U.S. federal income tax rate		(34.0	)%		(34.0	)%		(34.0	)%
	State income taxes, net of federal benefit		(6.4	)		(1.6	)		(1.2	)
	Canadian income taxes		8			(6.5	)		(8.5	)
	Nondeductible expenses and other		4			(0.4	)		1
	U.S. research and development credits		(0.7	)		—			(0.3	)
	Change in valuation allowance, federal and state		37.1			36			34.5

	Effective tax rate		8	%		(6.5	)%		(8.5	)%

Components of Total Deferred Tax Assets (Liabilities)	Significant components of our deferred tax assets (liabilities) as of December 31, 2014 and 2013 are as follows:


		2014			2013
	Deferred tax assets (liabilities):
	Net operating loss carryforwards	$	28,547		$	25,751
	Inventories		1,758			1,531
	Capitalized research and development costs		4,528			5,276
	Accruals and reserves currently not deductible		2,528			2,048
	Acquired intangible assets		(3,978	)		(5,099	)
	Depreciation and amortization		(485	)		114
	Stock-based compensation		5,369			4,704
	Investment tax credit carryforward		597			1,230
	Research and development tax credit carryforward		1,833			2,076

	Net deferred tax asset		40,697			37,631
	Valuation allowance		(44,072	)		(40,997	)

	Net deferred tax liability	$	(3,375	)	$	(3,366	)

Expiry Details of Federal Net Operating Losses Carryforwards	Our Federal NOL carryforwards expire as follows:


	Year of Expiration	NOLs
	2018 - 2019	$	16,377
	2020 - 2024		16,398
	2025 - 2031		14,476
	2032 - 2034		33,416

		$	80,667

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:


		2014			2013			2012
	Balance as of January 1	$	2,051		$	2,011		$	2,015
	Additions for tax positions of prior periods		25			40			67
	Reductions for tax positions of prior periods		(3	)		—			(71	)

	Balance as of December 31	$	2,073		$	2,051		$	2,011

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2014
Equity [Abstract]
Weighted-Average Assumptions for Fair Value Measurement	The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:


			Years Ended December 31,
			2014			2013			2012
	Black-Scholes Option Valuation Assumptions
	Risk-free interest rate(1)			2.13	%		1.47	%		0.99	%
	Expected dividend yield			—			—			—
	Expected stock price volatility(2)			50	%		51	%		52	%
	Expected life of stock options (in years)(2)			7			7			6

	(1)	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.
	(2)	Based upon historical experience.
Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options	Compensation expense recognized in the financial statements related to stock options was as follows:


			Years Ended December 31,
			2014			2013			2012
	Total compensation cost during the year		$	3,081		$	2,694		$	2,262
	Amounts capitalized into inventory during the year			(148	)		(128	)		(90	)
	Amounts recognized in cost of products sold for amounts previously capitalized			128			99			58

	Amounts charged against income		$	3,061		$	2,665		$	2,230

Summary of Company's Stock Option Activity	The following table summarizes the stock option activity under the Stock Plan:


			Options			Weighted-Average			Weighted-Average			Aggregate
						Exercise Price Per			Remaining			Intrinsic
						Share			Contractual Term			Value
	Outstanding on January 1, 2012			5,416		$	6.89
	Granted			783			11.18
	Exercised			(1,476	)		6.8
	Expired			(12	)		6.07
	Forfeited			(67	)		7.49

	Outstanding on December 31, 2012			4,644			7.64
	Granted			984			6.94
	Exercised			(80	)		5.07
	Expired			(82	)		7.59
	Forfeited			(195	)		7.87

	Outstanding on December 31, 2013			5,271			7.54
	Granted			1,202			5.77
	Exercised			(249	)		5.09
	Expired			(388	)		8.38
	Forfeited			(96	)		7.43

	Outstanding on December 31, 2014			5,740		$	7.22			6.3		$	18,084

	Vested or expected to vest as of December 31, 2014			5,679		$	7.23			6.3		$	17,826

	Exercisable on December 31, 2014			3,844		$	7.52			5.2		$	11,028

Schedule of Currently Outstanding and Exercisable Stock Options	The following table summarizes information about stock options outstanding as of December 31, 2014:


	Options outstanding											Options exercisable
	Range of exercise prices		Number			Weighted-			Weighted-			Number		Weighted-
			Outstanding			Average			Average			Exercisable		Average
						Remaining			Exercise					Exercise
						Contractual			Price Per					Price Per
						Term			Share					Share
						(in years)
	$2.55 - $5.19			726			7.8		$	4.49			726	$	4.49
	$5.60			92			0.1			5.6			92		5.6
	$5.71			1,136			9.1			5.71			—		—
	$5.72 - $6.37			217			7.2			5.96			146		5.96
	$6.63			670			5.9			6.63			643		6.63
	$6.67 - $6.99			29			9			6.93			1		6.67
	$7.05			758			8			7.05			355		7.05
	$7.33 - $8.28			847			3.4			8.02			804		8.05
	$8.33 - $10.89			597			1.5			9.35			593		9.34
	$10.99 - $12.14			668			6.9			11.29			484		11.29

				5,740			6.3		$	7.22			3,844	$	7.52

Summary of Restricted Stock Award Activity under Stock Plan	The following table summarizes restricted stock award activity under the Stock Plan:


			Shares			Weighted-Average
						Grant Date Fair
						Value
	Issued and unvested, January 1, 2012			879		$	5.91
	Granted			259			11.31
	Vested			(454	)		5.56
	Forfeited			(14	)		7.77

	Issued and unvested, December 31, 2012			670			8.19
	Granted			438			6.3
	Vested			(395	)		7.81
	Forfeited			(60	)		8.27

	Issued and unvested, December 31, 2013			653			7.15
	Granted			506			5.82
	Vested			(428	)		6.65
	Forfeited			(24	)		7.38

	Issued and unvested, December 31, 2014			707		$	6.5

	Issued and expected to vest, December 31, 2014			707		$	6.5

Business_Segment_Information_T

Business Segment Information (Tables)	12 Months Ended
Business Segment Information (Tables)	Dec. 31, 2014
Segment Reporting [Abstract]
Summary of Segment Information	The following table summarizes segment information for the years ended December 31, 2014, 2013, and 2012:


		Years Ended December 31,
		2014			2013			2012
	Net revenues:
	OSUR	$	82,686		$	78,559		$	73,562
	DNAG		23,778			20,381			14,258

	Total	$	106,464		$	98,940		$	87,820

	Operating income (loss):
	OSUR	$	(8,324	)	$	(12,849	)	$	(13,395	)
	DNAG		3,522			687			(2,875	)

	Total	$	(4,802	)	$	(12,162	)	$	(16,270	)

	Depreciation and amortization:
	OSUR	$	3,254		$	3,225		$	3,530
	DNAG		3,053			3,327			3,720

	Total	$	6,307		$	6,552		$	7,250

	Capital expenditures:
	OSUR	$	2,170		$	1,687		$	1,794
	DNAG		835			775			225

	Total	$	3,005		$	2,462		$	2,019


		December 31,
		2014			2013
	Total assets:
	OSUR	$	136,542		$	130,848
	DNAG		53,091			53,397

	Total	$	189,633		$	184,245

Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area	The following table represents total net revenues by geographic area, based on the location of the customer:


		Years Ended December 31,
		2014			2013			2012
	United States	$	82,256		$	77,194		$	67,460
	Europe		13,913			11,081			10,131
	Other regions		10,295			10,665			10,229

		$	106,464		$	98,940		$	87,820

	The following table represents total long-lived assets by geographic area:


		December 31,
		2014			2013
	United States	$	16,570		$	16,925
	Canada		1,353			975
	Other regions		11			33

		$	17,934		$	17,933

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule for Future Minimum Payments under Sublicense Agreement	Future minimum payments under this agreement are as follows:


	2015	$	500
	2016		500
	2017		500
	2018		292

		$	1,792

Schedule for Future Minimum Lease Payments under Operating Lease Agreements	Future payments required under these non-cancelable leases are as follows:


	2015	$	380
	2016		6

		$	386

Quarterly_Data_Tables

Quarterly Data (Tables)	12 Months Ended
Quarterly Data (Tables)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Results of Operations	The following tables summarize the quarterly results of operations for each of the quarters in 2014 and 2013. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein.


			2014 Results
			Three months ended
			March 31,			June 30,			September 30,			December 31,
			2014			2014			2014			2014
	Net revenues		$	23,537		$	26,401		$	27,845		$	28,681
	Costs and expenses			29,155			23,904	(1)		26,963			31,244

	Operating income (loss)			(5,618	)		2,497			882			(2,563	)
	Other income (expense), net			118			(142	)		268			287

	Income (loss) before income taxes			(5,500	)		2,355			1,150			(2,276	)
	Income tax expense (benefit)			131			(174	)		10			376

	Net income (loss)		$	(5,631	)	$	2,529		$	1,140		$	(2,652	)

	Earnings (loss) per share
	Basic		$	(0.10	)	$	0.05		$	0.02		$	(0.05	)

	Diluted		$	(0.10	)	$	0.04		$	0.02		$	(0.05	)


	(1)	Includes a $5.5 million gain from the termination of the Company’s oral fluid assay collaboration with Roche Diagnostics, which was recorded as a reduction of operating expenses in the indicated period.


			2013 Results
			Three months ended
			March 31,			June 30,			September 30,			December 31,
			2013			2013			2013			2013
	Net revenues		$	21,164		$	24,337		$	24,671		$	28,768	(2)
	Costs and expenses			31,753			29,913			26,731			22,705	(3)

	Operating income (loss)			(10,589	)		(5,576	)		(2,060	)		6,063
	Other income (expense), net			(47	)		42			41			164

	Income (loss) before income taxes			(10,636	)		(5,534	)		(2,019	)		6,227
	Income tax expense (benefit)			(410	)		(249	)		(127	)		14

	Net income (loss)		$	(10,226	)	$	(5,285	)	$	(1,892	)	$	6,213

	Earnings (loss) per share
	Basic		$	(0.18	)	$	(0.10	)	$	(0.03	)	$	0.11

	Diluted		$	(0.18	)	$	(0.10	)	$	(0.03	)	$	0.11


	(2)	Includes a non-recurring net favorable $2.5 million adjustment to account for a change in the Company’s revenue recognition policy related to its OraQuick® In-Home HIV tests.
	(3)	Includes an $8.3 million gain from the termination of the Company’s oral fluid assay collaboration with Roche Diagnostics, which was recorded as a reduction of operating expenses in the current period.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended			12 Months Ended			1 Months Ended
Share data in Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2014	Dec. 21, 2014
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Securities	Dec. 31, 2012	Jul. 31, 2014	Dec. 21, 2014
Product Information [Line Items]
Interest Paid				$0	$0	$199,000
Foreign and state income taxes paid				31,000	27,000	22,000
Increase or decrease in allowance for doubtful accounts				253,000	18,000	115,000
Accruals for purchases of property and equipment	217,000	0	0
Available-for-sale securities, fair value	5,000,000			5,000,000
Available-for-sale securities		0			0
Payments received for sale of exclusive rights				75,000,000
Expiration date of rights agreement				31-Dec-19
Revenue recognition, milestone method description				We will be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the life of the agreement. The first performance-based milestone period ends on December 31, 2015.
Reserve for sales return and allowances				437,000	279,000
Deferred revenue	8,043,000	1,119,000		8,043,000	1,119,000
Concentration rate of accounts receivable	10.00%			10.00%
Concentration rate of net revenues	10.00%			10.00%
Advertising expenses				6,910,000	17,142,000	6,310,000
Number of anti-dilutive securities excluded from EPS computation				6,447	5,924	5,314
Accumulated foreign currency adjustments included in other comprehensive loss amounted	-4,051,000	-3,131,000	1,298,000	-4,051,000	-3,131,000	1,298,000
Fair value of plan assets	1,234,000	677,000		1,234,000	677,000
Up Front Payment Arrangement [Member]
Product Information [Line Items]
Deferred revenue		1,119,000			1,119,000			613,000
AbbVie [Member]
Product Information [Line Items]
Deferred revenue							7,430,000
Deferred revenue payment received							15,000,000
Guaranteed Investment Certificates [Member]
Product Information [Line Items]
Available-for-sale securities, amortized cost	5,000,000			5,000,000
Available-for-sale securities, fair value	5,000,000			5,000,000
Maximum [Member]
Product Information [Line Items]
Useful life of Intangible assets				15 years
Additional annual payments to be received for sale of exclusive rights				55,500,000
Maximum [Member] \| Building [Member]
Product Information [Line Items]
Estimated useful lives of assets				40 years
Maximum [Member] \| Computer Equipment [Member]
Product Information [Line Items]
Estimated useful lives of assets				10 years
Maximum [Member] \| Machinery and Equipment [Member]
Product Information [Line Items]
Estimated useful lives of assets				10 years
Maximum [Member] \| Furniture and Fixtures [Member]
Product Information [Line Items]
Estimated useful lives of assets				10 years
Minimum [Member]
Product Information [Line Items]
Useful life of Intangible assets				1 year
Additional annual payments to be received for sale of exclusive rights				$3,500,000
Minimum [Member] \| Building [Member]
Product Information [Line Items]
Estimated useful lives of assets				20 years
Minimum [Member] \| Computer Equipment [Member]
Product Information [Line Items]
Estimated useful lives of assets				2 years
Minimum [Member] \| Machinery and Equipment [Member]
Product Information [Line Items]
Estimated useful lives of assets				2 years
Minimum [Member] \| Furniture and Fixtures [Member]
Product Information [Line Items]
Estimated useful lives of assets				2 years
DNA Genotek [Member]
Product Information [Line Items]
Number of third-party suppliers to manufacture DNAG's products				2

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Inventory, Net [Abstract]
Raw materials	$8,539	$6,700
Work in process	898	833
Finished goods	6,326	3,911
Inventories	$15,763	$11,444

Property_and_Equipment_Schedul

Property and Equipment - Schedule of Property and Equipment (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$49,350	$46,323
Less accumulated depreciation	-31,416	-28,390
Property plant and equipment Net	17,934	17,933
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,118	1,118
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	18,168	16,977
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	20,768	19,199
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	7,238	6,443
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,765	1,731
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$293	$855

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Depreciation expense	$3,123	$3,026	$3,347

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Beginning Balance	$23,782	$25,445
Decrease related to foreign currency translation	-2,048	-1,663
Ending Balance	$21,734	$23,782

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Gross	$33,732	$36,714
Accumulated Amortization	-16,227	-14,488
Net	17,505	22,226
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	1 year
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Gross	10,779	11,795
Accumulated Amortization	-3,508	-2,701
Net	7,271	9,094
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross	10,449	10,449
Accumulated Amortization	-7,957	-7,466
Net	2,492	2,983
Patents and Product Rights [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	3 years	3 years
Patents and Product Rights [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	7 years	7 years
Gross	8,372	9,162
Accumulated Amortization	-3,833	-2,952
Net	4,539	6,210
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years	15 years
Gross	4,132	4,521
Accumulated Amortization	-929	-715
Net	3,203	3,806
Non-compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross		787
Accumulated Amortization		-654
Net		$133
Non-compete Agreements [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)		1 year
Non-compete Agreements [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)		3 years

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets - Summary of Patents and Products Rights (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	$33,732	$36,714
Less accumulated amortization	-16,227	-14,488
Patent and products right, Net	17,505	22,226
HIV-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	1,900	1,900
HCV-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	4,500	4,500
Lateral Flow-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	1,500	1,500
Cryosurgery-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	2,549	2,549
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	10,449	10,449
Less accumulated amortization	-7,957	-7,466
Patent and products right, Net	$2,492	$2,983

Goodwill_and_Other_Intangible_5

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$3,184	$3,526	$3,903

Goodwill_and_Other_Intangible_6

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2015	$3,016
2016	3,016
2017	3,016
2018	3,012
2019	1,826
Beyond	$3,619

Accrued_Expenses_Schedule_of_A

Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities, Current [Abstract]
Payroll and related benefits	$6,620	$5,827
Royalties	2,285	4,374
Professional fees	480	749
Other	1,747	2,082
Accrued Expenses, Total	$11,132	$13,032

Income_Taxes_Schedule_of_Incom

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
United States									($8,282)	($12,833)	($13,515)
Canada									4,011	871	-2,997
Loss before income taxes	($2,276)	$1,150	$2,355	($5,500)	$6,227	($2,019)	($5,534)	($10,636)	($4,271)	($11,962)	($16,512)

Income_Taxes_Components_of_Inc

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current
Federal									$0	$0	$0
State									0	0	0
Canada									49
Total current income tax expense (benefit)									49
Deferred
Federal									-2,248	-4,280	-4,370
State									-827	-323	-272
Canada									294	-772	-1,397
Total deferred income tax expense (benefit)									-2,781	-5,375	-6,039
Increase in valuation allowance									3,075	4,603	4,642
Deferred income taxes									294	-772	-1,397
Total income tax expense (benefit)	$376	$10	($174)	$131	$14	($127)	($249)	($410)	$343	($772)	($1,397)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 29, 2000	Jun. 30, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 29, 2000
	Companies	Jun. 30, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 29, 2000
Income Tax Disclosure [Abstract]
Foreign tax expense (benefits)			$343	($772)	($1,397)
Adjustment to deferred tax liability		428
U.S. federal income tax benefits			0	0	0
U.S. state income tax benefits			0	0	0
Number of companies merged	2
Utilization of NOLs generated prior limited to							13,700
Gross unrecognized tax benefits			$2,073	$2,051	$2,011	$2,015

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	-34.00%	-34.00%	-34.00%
State income taxes, net of federal benefit	-6.40%	-1.60%	-1.20%
Canadian income taxes	8.00%	-6.50%	-8.50%
Nondeductible expenses and other	4.00%	-0.40%	1.00%
U.S. research and development credits	-0.70%		-0.30%
Change in valuation allowance, federal and state	37.10%	36.00%	34.50%
Effective tax rate	8.00%	-6.50%	-8.50%

Income_Taxes_Components_of_Tot

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets (liabilities):
Net operating loss carryforwards	$28,547	$25,751
Inventories	1,758	1,531
Capitalized research and development costs	4,528	5,276
Accruals and reserves currently not deductible	2,528	2,048
Acquired intangible assets	-3,978	-5,099
Depreciation and amortization	-485	114
Stock-based compensation	5,369	4,704
Investment tax credit carryforward	597	1,230
Research and development tax credit carryforward	1,833	2,076
Net deferred tax asset	40,697	37,631
Valuation allowance	-44,072	-40,997
Net deferred tax liability	($3,375)	($3,366)

Income_Taxes_Expiry_Details_of

Income Taxes - Expiry Details of Federal Net Operating Losses Carryforwards (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$80,667
2018-2019 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	16,377
2020-2024 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	16,398
2025-2031 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	14,476
2032 - 2034 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$33,416

Income_Taxes_Reconciliation_of1

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance as of January 1	$2,051	$2,011	$2,015
Additions for tax positions of prior periods	25	40	67
Reductions for tax positions of prior periods	-3		-71
Balance as of December 31	$2,073	$2,051	$2,011

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jul. 11, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 11, 2012	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price		75.00%
Granted exercise periods		10 years
Option vesting period		4 years
Vesting of Options		Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.
Shares available for future grants under the Stock Plan		4,770,000
Net cash proceeds from the exercise of stock options		$1,115,000	$409,000	$10,040,000
Income tax benefit realized from stock option exercises during period		0	0	0
Total compensation cost		5,744,000	5,572,000	5,197,000
Amount share repurchase program of common shares						25,000,000
Public offering, number of shares	6,100,000
Public offering, price per share	$12.30				$12.30
Proceeds from public offering before expenses	75,030,000			70,246,000
Underwriting discounts and commissions	4,502,000
Additional offering expenses	282,000
Share Repurchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired		0	0	0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of stock options granted		$3.03	$3.58	$5.38
Aggregate intrinsic value of options exercised		901,000	125,000	6,961,000
Unrecognized compensation expense related to unvested option awards		5,412,000
Expected weighted-average period for recognition of compensation expense related to unvested awards		2 years 7 months 6 days
Net cash proceeds from the exercise of stock options		1,115,000	409,000	10,040,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognition of compensation expense related to unvested awards		1 year 8 months 12 days
Total compensation cost		2,663,000	2,878,000	2,894,000
Unrecognized compensation expense related to unvested restricted stock awards		2,505,000
Vesting of restricted shares and exercise of stock options, withholding and exercise obligations		122,000	124,000	142,000
Restricted shares of common stock and stock options, aggregate values		$639,000	$829,000	$1,560,000

Stockholders_Equity_WeightedAv

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	2.13%	1.47%	0.99%
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock price volatility	50.00%	51.00%	52.00%
Expected life of stock options (in years)	7 years	7 years	6 years

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Total compensation cost during the year	$3,081	$2,694	$2,262
Amounts capitalized into inventory during the year	-148	-128	-90
Amounts recognized in cost of products sold for amounts previously capitalized	128	99	58
Amounts charged against income	$3,061	$2,665	$2,230

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding, Beginning Balance	5,271	4,644	5,416
Options, Granted	1,202	984	783
Options, Exercised	-249	-80	-1,476
Options, Expired	-388	-82	-12
Options, Forfeited	-96	-195	-67
Options, Outstanding, Ending Balance	5,740	5,271	4,644
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance	$7.54	$7.64	$6.89
Options, Vested or expected to vest	5,679
Weighted-Average Exercise Price Per Share, Granted	$5.77	$6.94	$11.18
Options, Exercisable	3,844
Weighted-Average Exercise Price Per Share, Exercised	$5.09	$5.07	$6.80
Weighted-Average Exercise Price Per Share, Expired	$8.38	$7.59	$6.07
Weighted-Average Exercise Price Per Share, Forfeited	$7.43	$7.87	$7.49
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance	$7.22	$7.54	$7.64
Weighted-Average Exercise Price Per Share, Vested or expected to vest	$7.23
Weighted-Average Exercise Price Per Share, Exercisable	$7.52
Weighted-Average Remaining Contractual Term, Outstanding	6 years 3 months 18 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	6 years 3 months 18 days
Weighted-Average Remaining Contractual Term, Exercisable	5 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding	$18,084
Aggregate Intrinsic Value, Vested or expected to vest	17,826
Aggregate Intrinsic Value, Exercisable	$11,028

Stockholders_Equity_Schedule_o1

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding, Options outstanding	5,740
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 3 months 18 days
Weighted-Average Exercise Price Per Share, Options outstanding	$7.22
Number Exercisable, Options exercisable	3,844
Weighted-Average Exercise Price Per Share, Options exercisable	$7.52
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	$2.55
Range of exercise prices, Upper Range Limit	$5.19
Number Outstanding, Options outstanding	726
Weighted-Average Remaining Contractual Term (in years), Options outstanding	7 years 9 months 18 days
Weighted-Average Exercise Price Per Share, Options outstanding	$4.49
Number Exercisable, Options exercisable	726
Weighted-Average Exercise Price Per Share, Options exercisable	$4.49
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$5.60
Number Outstanding, Options outstanding	92
Weighted-Average Remaining Contractual Term (in years), Options outstanding	1 month 6 days
Weighted-Average Exercise Price Per Share, Options outstanding	$5.60
Number Exercisable, Options exercisable	92
Weighted-Average Exercise Price Per Share, Options exercisable	$5.60
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$5.71
Number Outstanding, Options outstanding	1,136
Weighted-Average Remaining Contractual Term (in years), Options outstanding	9 years 1 month 6 days
Weighted-Average Exercise Price Per Share, Options outstanding	$5.71
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	$5.72
Range of exercise prices, Upper Range Limit	$6.37
Number Outstanding, Options outstanding	217
Weighted-Average Remaining Contractual Term (in years), Options outstanding	7 years 2 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$5.96
Number Exercisable, Options exercisable	146
Weighted-Average Exercise Price Per Share, Options exercisable	$5.96
Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$6.63
Number Outstanding, Options outstanding	670
Weighted-Average Remaining Contractual Term (in years), Options outstanding	5 years 10 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$6.63
Number Exercisable, Options exercisable	643
Weighted-Average Exercise Price Per Share, Options exercisable	$6.63
Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	$6.67
Range of exercise prices, Upper Range Limit	$6.99
Number Outstanding, Options outstanding	29
Weighted-Average Remaining Contractual Term (in years), Options outstanding	9 years
Weighted-Average Exercise Price Per Share, Options outstanding	$6.93
Number Exercisable, Options exercisable	1
Weighted-Average Exercise Price Per Share, Options exercisable	$6.67
Range Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$7.05
Number Outstanding, Options outstanding	758
Weighted-Average Remaining Contractual Term (in years), Options outstanding	8 years
Weighted-Average Exercise Price Per Share, Options outstanding	$7.05
Number Exercisable, Options exercisable	355
Weighted-Average Exercise Price Per Share, Options exercisable	$7.05
Range Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	$7.33
Range of exercise prices, Upper Range Limit	$8.28
Number Outstanding, Options outstanding	847
Weighted-Average Remaining Contractual Term (in years), Options outstanding	3 years 4 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$8.02
Number Exercisable, Options exercisable	804
Weighted-Average Exercise Price Per Share, Options exercisable	$8.05
Range Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	$8.33
Range of exercise prices, Upper Range Limit	$10.89
Number Outstanding, Options outstanding	597
Weighted-Average Remaining Contractual Term (in years), Options outstanding	1 year 6 months
Weighted-Average Exercise Price Per Share, Options outstanding	$9.35
Number Exercisable, Options exercisable	593
Weighted-Average Exercise Price Per Share, Options exercisable	$9.34
Range Ten [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	$10.99
Range of exercise prices, Upper Range Limit	$12.14
Number Outstanding, Options outstanding	668
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 10 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$11.29
Number Exercisable, Options exercisable	484
Weighted-Average Exercise Price Per Share, Options exercisable	$11.29

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Restricted Stock Award Activity Under Stock Plan (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	653	670	879
Shares, Granted	506	438	259
Shares, Vested	-428	-395	-454
Shares, Forfeited	-24	-60	-14
Shares, Issued and unvested, Ending Balance	707	653	670
Shares, Issued and expected to vest	707
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance	7.15	8.19	5.91
Weighted-Average Grant Date Fair Value, Granted	5.82	6.3	11.31
Weighted-Average Grant Date Fair Value, Vested	6.65	7.81	5.56
Weighted-Average Grant Date Fair Value, Forfeited	7.38	8.27	7.77
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance	6.5	7.15	8.19
Weighted-Average Grant Date Fair Value, Issued and expected to vest	6.5

Termination_Settlement_Additio

Termination Settlement - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Unusual or Infrequent Item [Line Items]
Gain on contract termination settlement	$5,500,000	$8,300,000	$5,500,000	$8,300,000
Termination date			21-Nov-13
Notice period after termination of contract			5 years
Maximum [Member]
Unusual or Infrequent Item [Line Items]
Additional payment received relating to termination of contract			$5,500,000

Business_Segment_Information_A

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
	Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business_Segment_Information_S

Business Segment Information - Summary of Segment Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Net revenues	$28,681	$27,845	$26,401	$23,537	$28,768	$24,671	$24,337	$21,164	$106,464	$98,940	$87,820
Operating loss	-2,563	882	2,497	-5,618	6,063	-2,060	-5,576	-10,589	-4,802	-12,162	-16,270
Depreciation and amortization									6,307	6,552	7,250
Capital expenditures									3,005	2,462	2,019
Total assets	189,633				184,245				189,633	184,245
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues									82,686	78,559	73,562
Operating loss									-8,324	-12,849	-13,395
Depreciation and amortization									3,254	3,225	3,530
Capital expenditures									2,170	1,687	1,794
Total assets	136,542				130,848				136,542	130,848
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues									23,778	20,381	14,258
Operating loss									3,522	687	-2,875
Depreciation and amortization									3,053	3,327	3,720
Capital expenditures									835	775	225
Total assets	$53,091				$53,397				$53,091	$53,397

Business_Segment_Information_P

Business Segment Information - Presentation of Total Net Revenues and Long-Lived Assets by Geographic Area (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$28,681	$27,845	$26,401	$23,537	$28,768	$24,671	$24,337	$21,164	$106,464	$98,940	$87,820
Long-lived assets	17,934				17,933				17,934	17,933
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									82,256	77,194	67,460
Long-lived assets	16,570				16,925				16,570	16,925
Europe [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									13,913	11,081	10,131
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues									10,295	10,665	10,229
Long-lived assets	11				33				11	33
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$1,353				$975				$1,353	$975

Commitments_and_Contingencies_1

Commitments and Contingencies - Schedule for Future Minimum Payments under Sublicense Agreement (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$500
2016	500
2017	500
2018	292
Total	$1,792

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule for Future Minimum Lease Payments under Operating Lease Agreements (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$380
2016	6
Total	$386

Commitments_and_Contingencies_3

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Contractual Obligation Fiscal Year Maturity [Line Items]
Rent expense	$648	$600	$510
Outstanding non-cancellable purchase commitments	8,729
Required salary payment as per agreements with employees, next year	500
Required salary payment as per agreements with employees, second fiscal year	500
Employment Agreements [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Required salary payment as per agreements with employees, next year	2,324
Required salary payment as per agreements with employees, second fiscal year	$1,097

Retirement_Plans_Additional_In

Retirement Plans - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$4
Contributed to plan, net of forfeitures	565	553	592
Value of the assets associated with the plan	1,234	677
Total obligation under plan	1,234	677
RRSP [Member] \| DNA Genotek [Member]
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	2
Contributed to plan, net of forfeitures	$136	$126	$113

Quarterly_Data_Summary_of_Quar

Quarterly Data - Summary of Quarterly Results of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$28,681	$27,845	$26,401	$23,537	$28,768	$24,671	$24,337	$21,164	$106,464	$98,940	$87,820
Costs and expenses	31,244	26,963	23,904	29,155	22,705	26,731	29,913	31,753
Operating loss	-2,563	882	2,497	-5,618	6,063	-2,060	-5,576	-10,589	-4,802	-12,162	-16,270
Other income (expense), net	287	268	-142	118	164	41	42	-47	531	200	-70
Loss before income taxes	-2,276	1,150	2,355	-5,500	6,227	-2,019	-5,534	-10,636	-4,271	-11,962	-16,512
INCOME TAX EXPENSE (BENEFIT)	376	10	-174	131	14	-127	-249	-410	343	-772	-1,397
Net income (loss)	($2,652)	$1,140	$2,529	($5,631)	$6,213	($1,892)	($5,285)	($10,226)	($4,614)	($11,190)	($15,115)
Earnings (loss) per share
BASIC	($0.05)	$0.02	$0.05	($0.10)	$0.11	($0.03)	($0.10)	($0.18)	($0.08)	($0.20)	($0.29)
DILUTED	($0.05)	$0.02	$0.04	($0.10)	$0.11	($0.03)	($0.10)	($0.18)	($0.08)	($0.20)	($0.29)

Quarterly_Data_Summary_of_Quar1

Quarterly Data - Summary of Quarterly Results of Operations (Parenthetical) (Detail) (USD $)	3 Months Ended		12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Gain on contract termination	$5,500,000	$8,300,000	$5,500,000	$8,300,000
Non recurring revenue		$2,500,000